Viking Therapeutics

Viking
Therapeutics
Daniel Malowany2023-12-14T23:43:27-05:00

Project Description

Follow-On Offering
Common Stock
.

$175,800,000

Financial Advisor
September 2018

Project Details

Categories:

IPO

© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

© Copyright 2018 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

Project Description

Project Details

Categories:

Site Info

Legal

Disclosures

Contact Info

Recent Posts

Stay In Touch

Contact Info

Project Description

Project Details

Categories:

Related Projects

Site Info

Legal

Disclosures

Contact Info

Recent Posts

Stay In Touch

Contact Info